Unacylated Ghrelin is associated with the isolated low HDL-cholesterol obese phenotype independently of insulin resistance and CRP level

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Nogueira, Juan Patricio ^a   Maraninchi, Marie ^a   Béliard, Sophie ^b   Lorec, Anne Marie ^a   Berthet, Bruno ^a   Bégu Le Corroller, Audrey ^a   Dubois, Noémie ^a   Grangeot, Rachel ^a   Mattei, Catherine ^a   Gaudart, Jean ^a   Nicolay, Alain ^a   Portugal, Henri ^a   Vialettes, Bernard ^a   Valéro, René ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Adiponectin; Apolipoprotein; Cardiovascular risk; Ghrelin; HDL cholesterol; Inflammation; Insulin resistance; Lipids; Obesity

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOPROTEIN; C REACTIVE PROTEIN; FATTY ACID; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL;

ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLICALLY ABNORMAL OBESITY; METABOLICALLY HEALTHY OBESITY; OBESITY; PHENOTYPE; REST;

EID: 84857960321     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-17     Document Type: Article

References (36)

1. The metabolic syndrome. Eckel RH, Grundy SM, Zimmet PZ, Lancet 2005 365 1415 1428 10.1016/S0140-6736(05)66378-7 15836891 (Pubitemid 40523737)
2. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R, Lewington S, MacMahon S, Aromaa A, Baigent C, Carstensen J, Chen Z, Duffy S, Kromhout D, Neaton J, Rodgers A, Tominaga S, Törnberg S, Tunstall-Pedoe H, Chambless L, De Backer G, De Bacquer D, Kornitzer M, Whincup P, Wannamethee SG, Wald N, Morris R, et al. Lancet 2009 373 1083 1096 10.1016/S0140-6736(09)60318-4 19299006
3. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Adiels M, Olofsson SO, Taskinen MR, Boren J, Arterioscler Thromb Vasc Biol 2008 28 1225 1236 10.1161/ATVBAHA.107. 160192 18565848
4. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, N Engl J Med 2007 357 1301 1310 10.1056/NEJMoa064278 17898099 (Pubitemid 47481452)
5. Metabolically healthy but obese individuals. Karelis AD, Lancet 2008 372 1281 1283 10.1016/S0140-6736(08)61531-7 18929889
6. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR, Arch Intern Med 2008 168 1617 1624 10.1001/archinte.168.15.1617 18695075
7. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. McLaughlin T, Lamendola C, Liu A, Abbasi F, J Clin Endocrinol Metab 2011 96 1756 1760 10.1210/jc.2011-0615
8. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP, Hypertension 2009 53 577 584 10.1161/HYPERTENSIONAHA.108.110320 19237685
9. Role of adipocytokines in obesity-associated insulin resistance. Zou C, Shao J, J Nutr Biochem 2008 19 277 286 10.1016/j.jnutbio.2007.06.006 18054218 (Pubitemid 351503767)
10. Impacting obesity and glycemic control using a culturally-sensitive diabetes education program in Hispanic patients with type 2 diabetes. Peterson RM, Beeson L, Shulz E, Firek A, De Leon M, Balcazar H, Tonstad S, Cordero-Macintyre ZR, Int J Body Compos Res 2010 8 85 94 21318090
11. Nutrition and metabolism: non-alcoholic fatty liver disease-pathogenesis, cardiovascular risk and therapy. Watts GF, Gan SK, Curr Opin Lipidol 2008 19 92 94 10.1097/MOL.0b013e3282f41b4f 18196992
12. Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F, Exp Gerontol 2009 44 136 160 10.1016/j.exger.2008.11.003 19041386
13. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. Barazzoni R, Zanetti M, Ferreira C, Vinci P, Pirulli A, Mucci M, Dore F, Fonda M, Ciocchi B, Cattin L, Guarnieri G, J Clin Endocrinol Metab 2007 92 3935 3940 10.1210/jc.2006-2527 17652221 (Pubitemid 47607644)
14. Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Circulation 2005 112 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765 (Pubitemid 41532612)
15. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF, Arterioscler Thromb Vasc Biol 2006 26 1357 1363 10.1161/01.ATV.0000222015.76038.14 16614317 (Pubitemid 44305382)
16. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Rashid S, Watanabe T, Sakaue T, Lewis GF, Clin Biochem 2003 36 421 429 10.1016/S0009-9120(03)00078-X 12951168 (Pubitemid 37083556)
17. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Lopez-Miranda J, Williams C, Lairon D, Br J Nutr 2007 98 458 473 10.1017/S000711450774268X 17705891 (Pubitemid 47272862)
18. Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients. Beliard S, Nogueira JP, Maraninchi M, Lairon D, Nicolay A, Giral P, Portugal H, Vialettes B, Valero R, Diabet Med 2009 26 736 739 19573124
19. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH, Diabetes 2005 54 795 802 10.2337/diabetes.54.3.795 15734858 (Pubitemid 40322084)
20. The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM, J Clin Endocrinol Metab 2005 90 4255 4259 10.1210/jc.2005-0019 15870125 (Pubitemid 41058206)
21. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB, Diabetes Care 2004 27 1680 1687 10.2337/diacare.27.7.1680 15220246 (Pubitemid 38857444)
22. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF, J Clin Endocrinol Metab 2009 94 989 997 19116237
23. Adiponectin is an important determinant of apoA-I catabolism. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P, Arterioscler Thromb Vasc Biol 2006 26 1364 1369 10.1161/01.ATV.0000219611.50066.bd 16574896 (Pubitemid 44305383)
24. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA, Diabetes Care 2005 28 2181 2186 10.2337/diacare.28.9.2181 16123487 (Pubitemid 41242465)
25. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, Circulation 2011 123 2292 2333 10.1161/CIR.0b013e3182160726 21502576
26. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Tan CY, Vidal-Puig A, Biochem Soc Trans 2008 36 935 940 10.1042/BST0360935 18793164
27. Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin. Magkos F, Fabbrini E, McCrea J, Patterson BW, Eagon JC, Klein S, Diabetes Obes Metab 2010 12 584 590 20590733
28. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Kontush A, Chapman MJ, Pharmacol Rev 2006 58 342 374 10.1124/pr.58.3.1 16968945 (Pubitemid 44394906)
29. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O, Diabetes 2003 52 2546 2553 10.2337/diabetes.52.10. 2546 14514639 (Pubitemid 37210544)
30. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruckdorfer KR, Vanderpump MP, Srai KS, J Biol Chem 2003 278 8877 8880 10.1074/jbc.C200575200 12531885 (Pubitemid 36800362)
31. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Le NA, Ginsberg HN, Metabolism 1988 37 614 617 10.1016/0026-0495(88)90077-7 3133537
32. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. Brinton EA, Eisenberg S, Breslow JL, J Clin Invest 1991 87 536 544 10.1172/JCI115028 1899429
33. Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. Gylling H, Vega GL, Grundy SM, J Lipid Res 1992 33 1527 1539 1431577
34. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP, Barrett PH, J Clin Endocrinol Metab 2006 91 973 979 16368749 (Pubitemid 43357768)
35. Polymorphisms in the ghrelin gene are associated with serum high-density lipoprotein cholesterol level and not with type 2 diabetes mellitus in Koreans. Choi HJ, Cho YM, Moon MK, Choi HH, Shin HD, Jang HC, Kim SY, Lee HK, Park KS, J Clin Endocrinol Metab 2006 91 4657 4663 10.1210/jc.2005-2549 16954159 (Pubitemid 44833453)
36. Lack of association of ghrelin precursor gene variants and percentage body fat or serum lipid profiles. Martin GR, Loredo JC, Sun G, Obesity (Silver Spring) 2008 16 908 912 10.1038/oby.2007.125 (Pubitemid 351465654)